Patient Symptoms Are Better Measure Of Decongestant’s Efficacy – FDA
This article was originally published in The Tan Sheet
Executive Summary
The patient self-assessed nasal congestion symptom score, not nasal air resistance, is the preferred tool to evaluate the effectiveness of an oral nasal decongestant such as phenylephrine, according to a report by a division of FDA's Office of New Drugs
You may also be interested in...
Monograph System Challenges Underscored By Pediatric Cold Debate
Concerns about the safety and efficacy of nonprescription pediatric cough/cold products point to the need to re-examine the monograph system in the future, according to University of Florida pharmacy and pediatrics professor Leslie Hendeles, Pharm.D
Phenylephrine Efficacy Will Be Questioned In Citizen Petition
A pharmacy professor intends to file a citizen petition asking FDA to re-examine the effectiveness of the nasal decongestant phenylephrine after the agency refused a similar request by Congress
Waxman Seeks Phenylephrine NDAC Review; Cites Efficacy Concerns
Rep. Henry Waxman (D-Calif.) is calling for an FDA advisory panel to reconsider the efficacy of the nasal decongestant phenylephrine and re-evaluate its status as a monograph ingredient